Full Press Release Details
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York.
ARGX
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York
Key Takeaway: argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis